ArticleFrontiers in pharmacology2025
Prognostic value of the pre-treatment albumin-to-alkaline phosphatase ratio in patients with lower-grade glioma: a propensity score matching study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The albumin-to-alkaline phosphatase ratio (AAPR) has recently emerged as a novel prognostic biomarker in various solid tumors. However, its clinical value in lower-grade glioma (LGG) remains unclear. Methods: We performed propensity score matching (PSM) to balance baseline characteristics between groups. Restricted cubic spline (RCS) analysis was used to evaluate the nonlinear relationship between AAPR and survival outcomes. Survival differences were assessed using Kaplan-Meier analysis, and both univariate and multivariate Cox regression models were applied to identify independent prognostic factors. Finally, a predictive nomogram was developed to estimate 1-, 3-, and 5-year overall survival. Results: RCS analysis revealed a nonlinear relationship between AAPR and OS (p = 0.0349). Patients were stratified by the median AAPR value (0.704), and those in the AAPR-High group (≥0.704) had significantly better OS (log-rank p = 0.0042) and progression-free survival (PFS) (log-rank p = 0.042) than those in the AAPR-Low group. AAPR showed stronger prognostic value in low-risk subgroups. Higher AAPR was significantly associated with better OS in univariate (p = 0.005, HR = 0.541, 95% CI: 0.353-0.829) and multivariate Cox analyses (p = 0.046, HR = 0.630, 95% CI: 0.400-0.993). The AAPR-based nomogram demonstrated good predictive performance for 1-, 3-, and 5-year OS, validated in the PSM cohort. Discussion: Pre-treatment AAPR is a simple, non-invasive, and effective biomarker for predicting prognosis in LGG patients, particularly those at lower clinical risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.